Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Sunnybrook Health SciencesToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sunnybrook Health Sciences Centre
- Trial code
- NCT05023265
- Record updated
- 28 April 2026
- Original description
This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).Read full original descriptionShow less
Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study
This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).
Inclusion: Patients ≥18 years old; Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months); Primary lesion >3 cm, or recurrent lesion following local ablative therapy; Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting; ECOG 0-2; Written informed consent; Participants must be able to understand the English-language or with the aid of a translator.
Exclusion: Previous abdominal RT in vicinity of kidney preventing definitive SBRT; Evidence of distant metastatic disease; History of major radiosensitivity syndrome; Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer); Primary Lesion >20cm; Currently pregnant or lactating.